Treatment (Coronary Artery Disease)

Patient Treated in Non-Surgical Gene Therapy Treatment Trial

Published in Blood Weekly, May 25th, 1998

Collateral Therapeutics, Inc., San Diego, California, announced the commencement of a Phase I/II multi-center clinical trial to evaluate the company's non-surgical gene therapy for coronary artery disease.

The trial, which is placebo-controlled and double-blind, enrolls approximately 100 patients and is being conducted in 10 major cardiovascular centers in the U.S. by Berlex Laboratories, Inc., a subsidiary of Schering AG, Germany, in collaboration with Collateral Therapeutics, pursuant to a commercial Investigational New Drug application.

The trial evaluates safety and efficacy at six different dose levels of a one-time gene therapy treatment for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1998-05-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry